[ad_1]
The competitive Department of Defense Traumatic Brain Injury and Mental Health Research Program (TBIPHRP) Translational Research Award will fund the preclinical development of Biosplice’s DYRK inhibitor in traumatic brain injury (TBI) models. Offers.
SAN DIEGO, March 8, 2024 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”) today announced that Biosplice’s promising small molecules will be used to develop new treatments for traumatic brain injury. , announced a partnership with the Roskamp Institute (“Rothkamp”). DYRK (Dual Specificity Tyrosine Phosphorylation-Regulated Kinase) inhibitors were selected for funding by the Department of Defense Congressional Medical Research Program (CDMRP). As part of the collaboration, the Department of Defense TBIPHRP award will fund Roskamp’s preclinical development of a well-characterized traumatic brain injury model using Biosplice’s DYRK inhibitor. This translational research could lead to future clinical trials for patients with traumatic brain injury.
Data from this collaboration is expected to inform the development of Biosplice’s DYRK inhibitor class in the treatment of degenerative neurological conditions, including various tauopathies. Traumatic brain injury, along with Alzheimer’s disease, certain frontotemporal dementias, and amyotrophic lateral sclerosis (ALS), is a class of neurological diseases characterized by harmful tau protein aggregation. Because DYRK proteins play a critical role in the formation of harmful tau protein aggregates, Biosplice believes that its potent and selective DYRK inhibitors could constitute an effective first-in-class therapy. thinking about.
“We are pleased to collaborate with Roskamp on this exciting research program that seeks to address the large unmet need for effective treatments for traumatic brain injury,” said Yusuf, Chief Medical Officer, BioSplice.・Dr. Yajishi said. “His selection by the Department of Defense for the Biosplice/Roskamp collaboration is a testament to our years of development of his industry-leading, highly selective DYRK inhibitors.”
Erich Horsley, CFO and CBO of Biosplice, added: “Over the past decade, the team at Biosplice has significantly deepened our chemical and clinical expertise in selective inhibition of DYRK and CLK kinases. It will help us accelerate the development of new neurological treatments across the disease spectrum.”
This award builds on more than four years of scientific collaboration between Roskamp and Biosplice. Previous research conducted by Roskamp demonstrated efficacy in animal models of traumatic brain injury using Biosplice’s first-generation DYRK inhibitor.
About Roskamp:
Since its founding in 2003, the Roskamp Institute, a 501(c)(3) nonprofit organization, has been a leader in the global effort to better understand and treat mental illness. The research foundation of the Institute was established more than 10 years ago by the Institute’s two principal investigators, Drs. Michael Mullan and Fiona Crawford were key members of the pioneering team of scientists who discovered the first known mutation in the amyloid gene that causes early-onset Alzheimer’s disease in the early 1990s. Roskamp’s research focuses on Alzheimer’s disease, traumatic brain injury, post-traumatic stress disorder, Gulf War illness, and red tide.
About Biosplice:
Biosplice is at the forefront of research focused on the study and regulation of Cdc2-like kinases (CLKs) and dual specificity tyrosine-regulated kinases (DYRKs). These kinases play pivotal roles in cell cycle regulation, splicing, and neurodevelopment, making them important targets for therapeutic intervention in a variety of diseases such as osteoarthritis, cancer, neuropathy, and diabetes. . With a robust chemical platform for kinase inhibition and a deep understanding of kinase signaling pathways, Biosplice leverages cutting-edge technology to discover and develop highly selective kinase inhibitors. Biosplice’s clinical development drugs include lorecivivint (Phase 3) for osteoarthritis and certubivint for numerous cancers, with an extensive preclinical pipeline including Alzheimer’s disease, diabetes and other degenerative diseases .
For more information, please visit https://www.biosplice.com.
Corporate contact:
Eric Horsley
Biosplice Therapeutics, Inc.
erich.horsley@biosplice.com
858-365-0200
[ad_2]
Source link
